Company intelligence / Profile preview

FortuneRock

Beijing, China

Ownership: Private
Development stage: Other

Overview

FortuneRock is a China-based biotech company focused on developing long-acting therapeutics using its proprietary recombinant human serum albumin fusion protein technology. The company has a pipeline of 9 clinical trials and holds 26 patents in the US, China, and PCT. FortuneRock has raised $24 million in funding and announced plans for an initial public offering.

Modalities: Recombinant fusion protein
Industry: Biotech

Partnerships

Big 10 Pharma (U.S. technology rights)

Beyond the preview

Go deeper on FortuneRock.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FortuneRock.

Explore the full profile